Recent Updates
Recently added Catalysts
NVAX

NOVAVAX to Present at Citi 2011 Global Health Care Conference

Key Takeaway: ROCKVILLE, Md., Feb. 24, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the Citi 2011 Global Health Care Conference on March 3rd, 20

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~29 mo
Minimal dilution risk
Lead asset
SARS-CoV-2 rS/Matrix-M1 Adjuvant
Phase 3 · SARS-CoV-2 Infection

Full Press Release Details

ROCKVILLE, Md., Feb. 24, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the Citi 2011 Global Health Care Conference on March 3rd, 2011 at 8:30 am local time at the Hilton New York Hotel, New York, NY. A live audio-only webcast link for the presentation can be accessed via the Company website at www.novavax.com under Investors/Events, and a replay will be available for 90 days after the presentation.
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary virus-like particles (VLPs) technology and single-use bioprocessing system enables rapid vaccine development and production where and when it's needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.
Last updated: Feb 24, 2011